Wellcome Trust
Also known as: KEMRI/Welcome Trust Research Programme,Kilifi, Kenya | KEMRI-Wellcome Trust | KEMRI-Wellcome Trust Collaborative Research Program | Malawi Liverpool Wellcome Programme | Malawi-Liverpool-Wellcome Trust Clinical Research Programme | Wellcome | Wellcome Foundation Limited Wellcome Research Laboratories | Wellcome Leap Inc. | Wellcome Sanger Institute | Wellcome Trust | Wellcome Trust DBT India Alliance | Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge | Wellcome Trust Sanger Institute | Wellcome Trust Sanger Institute, UK | Wellcome Trust United Kingdom | WTCRF Birmingham
Highest phase reached
Phase 4
First clinical trial
Apr 1, 1982First marketed drug
Apr 22, 1986First NDA
Apr 22, 1986Last known activity
Oct 1, 2025
Timeline
1930s
- Jan 1, 1936
Wellcome Trust— Founded
1980s
- Apr 22, 1986
digoxin immune fab (ovine)— NDA Organization
- Apr 22, 1986
digoxin immune fab (ovine)— NDA Secondary Org
Drugs by trial phase (163 distinct, 142 trials)
Phase 4 (25 own, 0 via acquisition)
- acetazolamide
- cefixime
- artesunate
- pneumococcal 13-valent conjugate vaccine
- typhoid vi polysaccharide vaccine
- hepatitis a vaccine, inactivated
- yellow fever vaccine 17d strain
- multi-valent pneumococcal conjugate vaccine
- live attenuated chimeric japanese encephalitis vaccine
- menafrivac
- pneumococcal 7-valent conjugate vaccine
- 10-valent Pneumococcal Conjugate Vaccine
- azithromycin
- amodiaquine
- chloroquine
- +10 more
Phase 3 (39 own, 0 via acquisition)
Phase 2 (50 own, 0 via acquisition)
Phase 1 (29 own, 0 via acquisition)
Other trials (20 own, 0 via acquisition)
Indications
Studied for
- Acquired Immunodeficiency Syndrome
- Altitude Sickness
- Anemia
- Anemia, Iron-Deficiency
- Anemia, Sickle Cell
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Cardiovascular Diseases
- Cerebral Small Vessel Diseases
- Cerebrovascular Disorders
- Child Nutrition Disorders
- Clostridium Infections
- Communicable Diseases
- Coronavirus Infections
- Cryptosporidiosis
- Cytomegalovirus Infections
- Depression
- Depressive Disorder
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Diabetic Foot
- Diarrhea
- Dupuytren Contracture
- Dysentery, Bacillary
- Encephalitis
- Encephalitis, Japanese
- Fatty Liver
- Fever
- Foot Ulcer
- Glaucoma
- Hemorrhagic Fever, Ebola
- Hemorrhagic Fevers, Viral
- Hepatitis
- Hepatitis C
- Hepatitis C, Chronic
- HIV Infections
- Infections
- Inflammation
- Influenza, Human
- Influenza in Birds
- Latent Tuberculosis
- Leishmaniasis
- Leishmaniasis, Visceral
- Lung Diseases
- Malaria
- Malaria, Falciparum
- Malaria, Vivax
- Malnutrition
- Melanoma
- Meningitis
- Meningitis, Cryptococcal
- Meningitis, Fungal
- Meningococcal Infections
- Neonatal Sepsis
- Neuroblastoma
- Non-alcoholic Fatty Liver Disease
- Obesity
- Ocular Hypertension
- Paratyphoid Fever
- Perceptual Disorders
- Pneumococcal Infections
- Pneumonia
- Pneumonia, Pneumococcal
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Rhinitis
- Rhinitis, Allergic
- Rotavirus Infections
- Sepsis
- Severe Acute Malnutrition
- Severe Acute Respiratory Syndrome
- Stroke
- Syndrome
- Toxemia
- Tuberculosis
- Tuberculosis, Pulmonary
- Typhoid Fever
- Vasculitis
- Virus Diseases
- Vitamin D Deficiency
- Yellow Fever
Marketed drugs (1)
Recent trials (50)
- NCT06921213CollaboratorPhase 2Oct 1, 2025
- NCT06958198CollaboratorPhase 1Sep 15, 2025
- NCT07085702CollaboratorPhase 1Jul 31, 2025
- NCT07035769CollaboratorPhase 1Jun 18, 2025
- NCT06778564CollaboratorPhase 3Apr 30, 2025
- NCT06938867CollaboratorPhase 1/Phase 2Feb 25, 2025
- NCT06696482CollaboratorPhase 1/Phase 2Jan 31, 2025
- NCT06719219CollaboratorPhase 1Dec 31, 2024
- NCT07031128CollaboratorPhase 4Jun 11, 2024
- NCT06178666CollaboratorN/AMar 1, 2024
- NCT05959616CollaboratorPhase 1Mar 1, 2024
- NCT06178666OfficialN/AMar 1, 2024
- NCT06062238CollaboratorPhase 3Feb 29, 2024
- NCT05942599CollaboratorPhase 1Jul 21, 2023
- NCT05859412CollaboratorN/AApr 13, 2023
Details
- Founded
- London, GB Jan 1, 1936
- First NDA
- Apr 22, 1986
- Last known activity
- Oct 1, 2025
Designations held
- Orphan drug